FindTrial
Sign In

Clinical comparative study of Lashunadi Vati and Tiladi Vati on Polycystic Ovarian Syndrome

An open label double arm randomized comparative clinical trial to the efficacy of Lashunadi vati 500mg twice a day orally for 90 days and Tiladi Vati 500mg Twice a day orally for 90 days in Pushpaghni Jataharini with special reference to Polycystic Ovarian Syndrome - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104846
Enrollment
90
Registered
2026-02-26
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N926- Irregular menstruation, unspecified

Interventions

None listed

Sponsors

Dr Priyanka Dattatraya Nikam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: hirsutism oligomenorrhoea usg findings shows Polycystic ovarian syndrome

Exclusion criteria

Exclusion criteria: patients having gonadotropic hypogonadism premature ovarian failure Patients known case of Adrenal hyperplasia Diabetes mellitus Androgen secreting tumor cardiac disease Pregnant patient

Design outcomes

Primary

MeasureTime frame
study the effect of Lashunadi vati on Pushpaghni Jataharini study the effect of Tilvadi vati on Pushpaghni JatahariniTimepoint: 12 weeks—

Secondary

MeasureTime frame
compare the effect of Lashunadi vati & Tilvadi vati on Pushpaghni JatahariniTimepoint: 12 weeks—

Countries

India

Contacts

Public ContactDr Bhagyshri Mahavir Khot

R A Podar Ayurved Medical College and M A Podar Hospital Worli Mumbai

khotbhagyashri@gmail.com9850539489

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026